Production (Stage)
Arcutis Biotherapeutics, Inc.
ARQT
$13.98
$0.322.34%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -25.06M | -10.79M | -41.54M | -52.33M | -35.38M |
| Total Depreciation and Amortization | 3.13M | 458.00K | 1.43M | 351.00K | 358.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 9.24M | 11.15M | 9.22M | 11.13M | 8.86M |
| Change in Net Operating Assets | -17.69M | -1.57M | -3.80M | -4.27M | -5.44M |
| Cash from Operations | -30.38M | -748.00K | -34.69M | -45.12M | -31.60M |
| Capital Expenditure | -608.00K | 0.00 | -143.00K | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 12.36M | 34.88M | 84.92M | -62.14M | -28.70M |
| Cash from Investing | 11.75M | 34.88M | 84.78M | -62.14M | -28.70M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -100.00M | -- | -- | -- |
| Issuance of Common Stock | 395.00K | 2.59M | 394.00K | 1.46M | 161.76M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 395.00K | -97.41M | 394.00K | 1.46M | 161.76M |
| Foreign Exchange rate Adjustments | 4.00K | -234.00K | 98.00K | -26.00K | -73.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -18.23M | -63.52M | 50.58M | -105.83M | 101.39M |